December 30, 2008 - Top Cardiac Center Implements AutoPulse

INVESTOR CONTACT:

A. Ernest Whiton



Chief Financial Officer



ZOLL Medical Corporation



+1 (978) 421-9655





MEDIA CONTACTS:

Diane Egan

Kim Angelastro

ZOLL Medical Corporation

Publicis Consultants | PR

+1 (978) 421-9637

+1 (212)527-8866
 

degan@zoll.com

kim.angelastro@publicis-pr.com

 

TOP CARDIAC CENTER IN ILLINOIS IMPLEMENTS ZOLL AUTOPULSE

 

Provena St. Joseph Hospital Values AutoPulse for High-Quality CPR

 

December 30, 2008CHELMSFORD, Mass.—ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, announced today that Provena Saint Joseph Hospital in Elgin, Ill. has implemented the Company’s AutoPulse®  Non-Invasive Cardiac Support Pump in the hospital’s intensive care and cardiac care units.  The hospital was recently ranked the top hospital in the state of Illinois for cardiac surgery for 2009 by HealthGrades, the nation’s leading healthcare ratings company.

 

“The AutoPulse is like a member of our code team. It’s clinically vital. We’ve seen blood pressure return to normal in cardiac arrest patients, and we’re seeing the best codes on paper that we’ve ever had,” said Wanda Pritts, Critical Care Specialist. “The first time we used AutoPulse was on a large man, about 275 pounds.  We were able to get him back to a perfusable heart rhythm and shock him.  This would not have been possible with manual CPR.”

 

She added that staff is able to deploy the AutoPulse within 7-10 seconds, that it’s easy to use, and has a calming effect among the code team.  Plans are to introduce the automatic chest compression device to other departments of the hospital in the future.

 

AutoPulse helps provide the consistent chest compressions called for by the 2005 American Heart Association Guidelines. It is an automated, portable device with an easy-to-use, load-distributing LifeBand® that squeezes the entire chest in an uninterrupted “hands-free” manner, improving blood flow to the heart and brain during cardiac arrest.

 

“We’re pleased that yet another highly-regarded cardiac center, like Provena Saint Joseph, realizes the value AutoPulse can provide in improving survival rates from sudden cardiac arrest,” said Richard A. Packer, Chairman and Chief Executive Officer of ZOLL.  “More and more hospitals, both large and small, are recognizing the importance that consistent, uninterrupted, high-quality chest compressions have in improving outcomes.”

 

About Sudden Cardiac Arrest

 

SCA claims more than 1 million lives each year worldwide. It is the leading cause of unexpected death in the world and strikes without warning. Currently, only about 5 percent of victims survive; 95 percent will die from SCA. SCA is an abrupt disruption of the heart’s function, which causes a lack of blood flow to vital organs.

 

About Provena Saint Joseph Hospital

 

Provena Saint Joseph Hospital is a 199-bed hospital, located in the city of Elgin, 40 miles northwest of Chicago. The hospital’s cardiovascular services provide the most advanced, comprehensive cardiac care in the area, from prevention and education to diagnosis and treatment, including advanced cardiac surgery, to rehabilitation and aftercare. Ranked the top hospital in Illinois for cardiac surgery for 2009 by HealthGrades, the nation’s leading healthcare ratings company, Provena Saint Joseph Hospital’s quality outcomes place them among the top 5% of all hospitals in the nation for cardiac surgery and overall cardiac services.

 

About ZOLL Medical Corporation

 

ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help® and See-Thru CPR®, that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.

 

ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. 2008 marks the 25th anniversary of ZOLL’s resuscitation product development. For more information, visit www.zoll.com.

 

Certain statements contained in this press release, including statements regarding the future business of the Company,  and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995).  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K filed with the SEC on December 8, 2008.  You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

 

Copyright © 2008 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, AutoPulse, LifeBand, Real CPR Help, and See-Thru CPR are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.